GlassScriptPhysician profile
Monica Gad
NPI 1770002362
$7,299.28
in general payments reported to CMS, 2019-2025
53 companies · $2,294 in 2025
The $2,294 reported for 2025 was more than what 93% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,645 · 2022: $1,092 · 2023: $1,131 · 2024: $1,136 · 2025: $2,294.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,273 · Education: $289.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,272.77 |
| Education | $288.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $654.52 | 2021-2025 | Lynparza, Brilinta |
| Abbvie INC. | $648.71 | 2021-2025 | |
| Novo Nordisk INC | $636.60 | 2021-2023 | Wegovy |
| Glaxosmithkline, LLC. | $508.02 | 2021-2025 | Shingrix, Zejula, Jemperli |
| Janssen Biotech, INC. | $445.11 | 2023-2025 | Tecvayli, Talvey, Erleada |
| Daiichi Sankyo INC. | $411.79 | 2021-2025 | Enhertu, Datroway |
| E.R. Squibb & Sons, L.L.C. | $331.84 | 2022-2025 | Opdivo, Augtyro, Krazati |
| Pfizer INC. | $330.58 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $326.47 | 2021-2025 | Keytruda, Lynparza |
| Novartis Pharmaceuticals Corporation | $314.96 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $198.60 | 2021-2025 | |
| Exelixis INC. | $188.14 | 2024-2025 | Cabometyx |
| Incyte Corporation | $180.44 | 2023-2025 | Jakafi |
| Regeneron Healthcare Solutions, INC. | $180.35 | 2023-2025 | Libtayo |
| Bayer Healthcare Pharmaceuticals INC. | $177.91 | 2022-2025 |
Show all 53 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $172.98 | 2021-2025 | Verzenio, Jaypirca, Retevmo |
| Syndax Pharmaceuticals, INC. | $168.55 | 2025 | Revuforj |
| Taiho Oncology, INC. | $105.22 | 2024-2025 | |
| Sumitomo Pharma America, INC. | $102.42 | 2023-2025 | Orgovyx |
| Amarin Pharma, INC. | $93.65 | 2021-2022 | |
| Corcept Therapeutics | $75.03 | 2021-2022 | |
| Bausch Health US, LLC | $72.95 | 2021-2022 | |
| Rigel Pharmaceuticals, INC. | $71.06 | 2025 | Rezlidhia, Tavalisse, Gavreto |
| Genentech USA, INC. | $68.85 | 2021-2025 | Columvi, Polivy, Lunsumio |
| Ipsen Biopharmaceuticals, INC | $63.75 | 2023 | Onivyde, Somatuline Depot |
| Astellas Pharma US INC | $62.67 | 2024-2025 | Xtandi |
| Geron Corporation | $53.74 | 2025 | Rytelo |
| Abbott Laboratories | $52.00 | 2022 | |
| Amgen INC. | $39.44 | 2022 | |
| Sanofi-Aventis U.S. LLC | $37.33 | 2021 | |
| Blueprint Medicines Corporation | $35.66 | 2023 | Ayvakit |
| Takeda Pharmaceuticals U.S.A., INC. | $34.70 | 2024 | Fruzaqla, Alunbrig |
| Puma Biotechnology, INC. | $34.68 | 2023-2025 | Nerlynx |
| Jazz Pharmaceuticals INC. | $33.69 | 2023 | |
| Beone Medicines USA, INC. | $27.35 | 2025 | Brukinsa |
| Agios Pharmaceuticals, INC. | $26.86 | 2025 | Pyrukynd |
| Seagen INC. | $25.12 | 2023 | Tukysa |
| Servier Pharmaceuticals LLC | $24.68 | 2025 | |
| Stemline Therapeutics INC. | $24.28 | 2023 | Orserdu |
| G1 Therapeutics, INC. | $24.25 | 2023 | Cosela |
| Eisai INC. | $23.26 | 2025 | |
| Azurity Pharmaceuticals, INC. | $21.42 | 2025 | Danziten |
| Genzyme Corporation | $21.24 | 2025 | |
| Octapharma USA, INC. | $21.22 | 2023 | Panzyga |
| Novocure INC. | $20.14 | 2025 | Optune Lua (Novottf-200t) |
| Mylan Specialty L.P. | $18.79 | 2021 | |
| Emd Serono, INC. | $18.68 | 2023 | Tepmetko |
| Pharmaessentia USA Corporation | $16.96 | 2025 | Besremi |
| Genentech, INC. | $15.90 | 2025 | Venclexta |
| Janssen Pharmaceuticals, INC | $15.61 | 2025 | Erleada |
| Seqirus USA INC | $14.79 | 2022 | |
| Phadia US INC. | $14.21 | 2022 | |
| Boston Scientific Corporation | $12.11 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Monica Gad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.